OmniAb, Inc. (OABI) 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing is the Annual Report on Form 10-K for OmniAb, Inc. for the fiscal year ended December 31, 2025. OmniAb is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech partners to enable the discovery of next-generation therapeutics. The company utilizes a proprietary platform featuring engineered transgenic animals (OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniUltra) and AI-driven screening tools (xPloration, OmniDeep) to identify fully human antibodies. As of December 31, 2025, the company reported 107 active partners and 407 active programs, including 27 antibodies in clinical development and three approved products commercialized by partners.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $18,666 | $26,391 |
| Net Loss | $(64,779) | $(62,033) |
| Operating Loss | $(68,969) | $(74,502) |
| Cash, Cash Equivalents & Short-Term Investments | $54,025 | $59,434 |
| Net Cash Used in Operating Activities | $(36,455) | $(39,664) |
| Net Cash Provided by Financing Activities | $27,914 | $13,020 |
Revenue Breakdown (2025): License and milestone revenue ($9.8M), Service revenue ($7.3M), xPloration revenue ($0.8M), and Royalty revenue ($0.9M).
Expense Breakdown (2025): Research and development ($47.8M), General and administrative ($29.2M), and Amortization of intangibles ($12.9M).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 29% to $18.7 million, driven by a 30% drop in license and milestone revenue and a 39% drop in service revenue. Service revenue declined due to the completion or discontinuation of certain small molecule ion channel programs.
- New Revenue Stream: The company launched the xPloration Partner Access Program in May 2025, generating $0.8 million in new revenue from instrument and consumable sales.
- Net Loss Increase: Net loss increased slightly by 4% to $64.8 million. This was despite a 13% reduction in total operating expenses, primarily due to lower personnel costs and share-based compensation.
- Impairment Charges: The company recorded $3.9 million in impairment charges in 2025 related to small molecule ion channel assets (property, equipment, and prepaid technology), compared to no such charges in 2024.
- Asset Sale: In May 2025, the company sold a small molecule Kv7.2 program to Angelini Pharma for $3.0 million, recorded as a gain in other operating income.
- Capital Raise: In August 2025, the company completed a private placement (PIPE) raising approximately $30.0 million gross proceeds. No shares were sold under the ATM facility in 2025, compared to $11.4 million in 2024.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes current cash, cash equivalents, and short-term investments ($54.0 million) are sufficient to fund operations for at least the next 12 months. The company anticipates continuing to incur losses as it invests in R&D and platform expansion. Long-term value is expected to be driven by royalties from partner product sales, though the timing and likelihood of these payments remain uncertain.
Key Risks and Contingencies:
- Partner Dependency: Revenue is heavily dependent on partners achieving milestones and commercializing products. Three partners accounted for 37% of 2025 revenue.
- Regulatory and Legislative: The Inflation Reduction Act (IRA) and the "One Big Beautiful Bill Act" (enacted July 2025) pose risks regarding drug pricing, Medicaid funding reductions, and Medicare price negotiations. The U.S. BIOSECURE Act (enacted Dec 2025) may restrict procurement from certain foreign biotechnology companies.
- Intellectual Property: The company relies on a portfolio of patents and in-licenses. Risks include the inability to maintain protection, challenges to patent validity, and reliance on third-party licensors.
- Market Volatility: The company's warrants are currently "out-of-the-money" (exercise price $11.50 vs. trading price ~$1.79), limiting potential cash inflows from warrant exercises.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $54.0 million cash balance against the current burn rate (~$36.5M operating cash outflow) to confirm the 12-month liquidity assertion.
- Revenue Concentration: Review the specific identities and financial health of the top three partners representing 37% of revenue to assess concentration risk.
- Impairment Rationale: Examine the details of the $3.9 million impairment charge regarding ion channel assets to understand the strategic shift away from small molecule programs.
- Warrant Status: Monitor the stock price relative to the $11.50 warrant exercise price; significant upside is required to unlock potential capital from the 19 million outstanding warrants.
- Regulatory Impact: Assess the potential impact of the newly enacted "One Big Beautiful Bill Act" and BIOSECURE Act on future partner contracts and supply chains.